Vitamin C: Cancer cure?

[Guest guest]

http://www.philly.com/mld/inquirer/living/health/14842932.htm

Posted on Sun, Jun. 18, 2006 in The Philadelphia Enquirer Health and

Science Section

 

 

Vitamin C: Cancer cure?

 

 

By Marie McCullough

 

 

Inquirer Staff Writer

 

Is mainstream medical science ignoring an inexpensive, painless, readily

available cure for cancer?

 

Mark Levine mulls this loaded question.

 

The government nutrition researcher has published new evidence that

suggests vitamin C can work like chemotherapy - only better. But so far,

he hasn't been able to interest cancer experts in conducting the kind of

conclusive studies that, one way or the other, would advance treatment.

 

" If vitamin C is useful in cancer treatment, that's wonderful. If it's

not, or if it's harmful, that's fine, too, " said Levine, a

Harvard-educated physician at the National Institute of Diabetes and

Digestive and Kidney Diseases. " The goal is: Find what's true. Either

way, the public wins, clinicians win, and patients win. "

 

If Linus Pauling, the two-time Nobel laureate turned vitamin C zealot,

had taken an equally dispassionate stance 30 years ago, who knows where

the vitamin would be in oncology today. Surely not where it is: a

dubious alternative on the fringes of medicine, despite its continuing

links to remissions and cures.

 

This is not about popping supplements. It's about putting high-dose

vitamin C, or ascorbic acid, into a vein, which requires needles and

trained professionals.

 

The distinction between oral and intravenous is crucial. The body

automatically gets rid of extra C through urine. Levine's lab has shown

that, at high concentrations, the vitamin is toxic to many types of

cancer cells in lab dishes. But to get that much C into the body before

it's eliminated, it must be put directly into the blood.

 

This may explain the defining setback of Pauling's crusade. He and his

collaborator, Scottish surgeon Ewan Cameron, gave C intravenously and

orally, and claimed many of their cancer patients lived surprisingly

long and well. In the 1970s, two rigorous government studies intended to

test their claims gave only pills - and found no benefits.

 

How could so many smart people, including Pauling, ignore a variable as

basic as the body's ability to absorb and clear a drug?

 

" I don't want to impugn anyone, " Levine said. " It's one of these things

where somebody didn't ask the right questions. "

 

So Levine keeps on, driven by the still-open question:

 

Can intravenous C do what even the costliest, most targeted, most

effective therapies cannot: kill cancer cells without harming healthy ones?

 

*500 oranges*

 

Loretta Hill, 42, of Pittsgrove, Salem County, sits at a faux granite

table, facing a TV, chatting with two other cancer patients in the

Marlton office suite of family physician Vivienne Matalon.

 

Each patient is tethered to an intravenous bag of C and other nutrients

hung above the table that will take 40 minutes to drip into them. The

fee, not usually covered by insurance, is $110.

 

Hill can't prove that C saved her from colon cancer, but she fervently

believes it has.

 

She was diagnosed in 2001, at age 38, after a sudden bout of rectal

bleeding. She had surgery, radiation, two courses of chemo. Six months

later, the cancer was back - but had spread to both lungs.

 

After those tumors were cut out, her oncologist offered irinotecan,

which costs about $9,500 a week. But, she says, he held out little hope.

He declined to be interviewed.

 

By then, Hill could barely function, much to the anguish of her husband

and 9-year-old daughter.

 

When she heard about Matalon's ascorbate infusions, she figured, " If

this doesn't work, at least I'll be in a better position for more chemo. "

 

Today, almost four years later, Hill is in college part time, plays

soccer, and has no signs of cancer. Her weekly C dosage has been cut to

30 grams - about 500 oranges' worth - but she has no plans to quit

because her only side effects are " fabulous hair and skin. "

 

Bill Nath, 69, a Wichita, Kan., businessman, is an even more provocative

case.

 

In 1996, blood in his urine led to a diagnosis of bladder cancer. Tumors

were invading the organ and surrounding muscle.

 

Nath consulted experts at four major cancer centers from Wichita to New

York. All recommended chemo, radiation, and removal of all or part of

the bladder. Total removal would include the prostate, adding risks of

incontinence and impotence.

 

One specialist " said if I didn't remove the whole bladder, I would die, "

said Nath. " It was pretty traumatic. "

 

Nath ultimately made a choice that seemed suicidal to his wife, friends,

and doctors: to keep part of his bladder and forgo chemo and radiation.

 

Instead, he got 30 grams of C twice a week for three months, then every

month or two for four years at the Center for the Improvement of Human

Functioning in Wichita. It was founded by Hugh Riordan, a physician and

friend of Pauling's, now deceased.

 

Today, a decade after his diagnosis, Nath is cancer-free.

 

Levine, in collaboration with National Cancer Institute pathologists,

reexamined, then published Nath's case and two others from Riordan's

center. While such " case reports " prove nothing, Levine hoped they would

stir interest in reexamining ascorbate in oncology.

 

But as Nath has discovered, when it comes to C, people who hear

hoofbeats look for zebras.

 

" Everybody thought I was crazy, " he said. " Now they probably think...

it's a miracle or something. "

 

*Not a miracle*

 

Vitamin C is not miraculous, proponents say. Just as some people die

despite standard treatment, some die despite ascorbate drips.

 

" We may not be able to affect the ultimate outcome, " said Matalon, who

sees about 15 ascorbate patients a week. " But I think we see a dramatic

improvement in quality of life. "

 

The problem is, anecdotes and impressions don't count. Skeptics ask:

Where's the data on dosing and regimens, on tumor responses, on survival?

 

" As far as I know, that kind of registry just doesn't exist now, and

it's a huge weakness of the movement, " acknowledged Ron Hunninghake,

chief medical officer at Riordan's center, which is starting a database.

 

In any case, as consumers clamor for alternative therapies, intravenous

C is gaining fans. Reports of side effects are rare, and risky patients

- with kidney problems or blood disorders - are easily screened out.

 

" Interest is definitely growing, " said Kenneth Bock, physician and

president of the American College for Advancement in Medicine, an

alternative-medicine society that teaches ascorbate infusion protocols.

 

Interest is not growing, however, among mainstream oncologists, judging

from conferences, publications, and interviews with some of them.

 

The National Cancer Institute, with a $5 billion budget, is not

sponsoring studies of intravenous C. Neither is the National Center for

Complementary and Alternative Medicine - although it is paying for

cancer studies of the noni extract herbal supplement and Reiki energy

healing. The American Cancer Society and the American Association of

Clinical Oncologists warn patients against high-dose C, as do leading

cancer centers such as the University of Pennsylvania's and Memorial

Sloan-Kettering in new York.

 

Jeffrey White, director of the National Cancer Institute's office of

cancer complementary and alternative medicine, said that he's tried to

" generate awareness " of Levine's research, and believes it justifies

more studies in humans. But White acknowledged that the NCI has rejected

" a few " proposals for such studies.

 

At the prestigious Mayo Clinic in Rochester, Minn., oncologist Edward

Creagan said the idea that intravenous, but not oral, levels are toxic

to cancer is " an intriguing concept. "

 

" However, my own belief is that the vitamin C story is really ancient

history, " he said. " It would be very difficult for patients and

clinicians to mount a lot of enthusiasm for another vitamin C study. "

 

It was Creagan and his Mayo colleague, Charles Moertel, since deceased,

who in the 1970s conducted the two NCI-funded " clinical trials " that

showed vitamin C pills were no better than placebo pills for cancer

patients.

 

A clinical trial is considered ultra-reliable because it is designed to

keep beliefs and hopes from slanting findings.

 

Pauling lobbied for a trial, then later contended that the Mayo

researchers enrolled unsuitable patients. A second trial in response to

Pauling's criticism also bombed. Again he faulted the Mayo oncologists.

He also threatened a libel suit against a Rochester newspaper for the

headline " Pauling Wrong on Vitamin C for Cancer, " and accused the New

England Journal of Medicine and the NCI of accepting a " fraudulent "

study, according to Australian medical historian Evelleen Richards.

 

By then, Pauling advocated treating everything from the common cold to

mental illness with vitamins and other substances he dubbed

" orthomolecular, " meaning " right molecule. " To many colleagues, this

genius and visionary, winner of the 1954 Nobel in chemistry and the 1962

Nobel Peace Prize for his antiwar work, had become a kook - " The Old Man

and the C " .

 

Decades later, both skeptics and fans of C are gun-shy about more trials.

 

" There's tremendous resistance to even test this, " Levine said. " It's

very hard to revisit something like this without data. Information is

diamonds. "

 

As the chief of the molecular and clinical nutrition section at the

National Institute of Diabetes and Digestive and Kidney Diseases -

hardly a hotbed of federal cancer research - Levine discovered some

diamonds " by accident. "

 

In the early 1990s, his lab began looking at how the concentration of a

nutrient affects its function, and how the body gets the proper

concentration.

 

" As part of those studies, we looked at how vitamin C is absorbed in the

intestine, " Levine said.

 

By 2000, when that work led to an increase in the U.S. recommended daily

allowance of vitamin C, Levine had become an expert on ascorbate's

" pharmacokinetics " - what the body does to the drug.

 

Consumers and scientists already knew that ascorbate was an

" antioxidant, " meaning it protects cells from reactive oxygen molecules

- the same marauders that turn peeled apples brown and wet metal rusty.

 

Indeed, the reason the American Cancer Society and others discourage

ascorbate megadoses is that a few studies of cells in dishes suggest C

might protect cancer from oxidant damage. Chemotherapy and radiation

work partly by intentionally unleashing this damage.

 

But Levine's lab-dish studies showed that ascorbate transforms from an

antioxidant into just the opposite - an oxidant /promoter/ - when it

reaches high concentrations. At these levels, which are achievable in

the body only intravenously, C acts like a toxic drug by generating

hydrogen peroxide, a powerful oxidant used as a bleaching agent, an

antiseptic, and even a World War II rocket fuel.

 

Still, the biochemistry was puzzling. Putting pure peroxide in the

bloodstream can be fatal, so why did patients feel fine when the vitamin

that produces it was dripped into their veins?

 

Levine's experiments offered possible answers. Vitamin C did not

generate peroxide in blood, only in liquid such as that found in body

cavities. Thus, in the body, intravenous C must seep out of the blood to

work.

 

Five out of nine types of cancer cells that were put in simulated

body-cavity fluid died when concentrated ascorbate or peroxide was added

to the dish. And the best part: This same lethal marinade had no effect

on healthy cells.

 

For some reason, cancer cells were like the Wicked Witch of the West

splashed with water - powerful villains vanquished by a mundane

substance that is harmless to good guys.

 

Previously, Riordan had speculated that this was partly because an

enzyme that neutralizes peroxide is abundant inside normal cells, and

scarce inside cancerous ones. But by inducing cells to take in C, Levine

proved that the internal concentration doesn't matter; malignant cells

withered only when C surrounded them.

 

Armed with this new evidence, a coterie of researchers - all associated

with Pauling or his disciples - have recently obtained private funding

for small trials of intravenous C.

 

University of Kansas Medical Center physician Jeanne Drisko has $375,000

for a trial of 30 ovarian cancer patients. In Montreal, McGill

University oncologist Wilson Miller has $300,000 to find the maximum

safe doses for treating various cancers.

 

Meanwhile, Levine is forging ahead with animal studies, trying to

decipher the molecular magic of C's selective toxicity.

 

Does that mean he believes C is an unsung cancer weapon?

 

" I think that question is akin to 'Do you still beat your wife?' " he

said. " The question I would ask is: Shouldn't we investigate the

potential of ascorbate as a drug?... Let's not guess anymore. Let's be

motivated by the truth. "

 

*Web Sites and Information*

 

For more information on the pros and cons of intravenous vitamin C use,

and where you might find the treatment:

 

.. The Center for the Improvement of Human Functioning in Wichita, Kan.,

specializes in certain alternative medical approaches, including

intravenous vitamin C: http://www.brightspot.org/

 

Its intravenous C treatment protocol can be found at:

http://www.canceraction.org.gg/recnac.htm

 

.. The American College for Advancement of Medicine is a medical society

that educates health-care professionals about alternative therapies. It

teaches vitamin C infusion protocols as part of training in chelation

therapy. It has a physician referral phone line (1-888-439-6891) and a

searchable online physician directory:

 

http://www.acam.org/dr_search/index.php

 

.. The American Cancer Society is a national research, education,

advocacy, and service organization. It offers information on alternative

therapies. A Web page on vitamin C is at:

http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Vitamin_C.

 

*asp?sitearea=ETO*

 

.. The National Cancer Institute's Office of Cancer Complementary and

Alternative Medicine has information about treatments, research, and

clinical trials:

 

http://www.cancer.gov/cam/

 

------

/Contact staff writer Marie McCullough at 215-854-2720 or

mmccullough <mmccullough./